Takeda Pharmaceutical Company Limited (TAK:NYSE) closed at $21.43 on November 13, 2026, up 1.47% on the day. The stock trades 1.4% below its 52-week high of $21.73 and 54.1% above its 52-week low of $13.91. Over the past year, it gained 50.0%. Takeda Pharmaceutical Company Limited is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 13, 2025, TAK closed higher on 126 days (50%). Its best day was July 2, 2026 (+5.14%) and its worst was June 1, 2026 (-4.82%). It never moved 10% or more in a single session.
Takeda is Japan's largest pharmaceutical company, with annual revenue around $16 billion and a focus on four therapeutic areas: oncology, gastroenterology, vaccines, and neurology. Roughly 40% of its revenue comes from Japan. The Millennium acquisition (2008) brought rights to Velcade, Ninlaro, and Entyvio. The Nycomed acquisition (2011) expanded Takeda's exposure to Europe and emerging markets. Other notable products include Azilva (blood pressure), leuprorelin (prostate cancer), and Trintellix (depression).
Find more stocks like TAK with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.